Session Details

Recent Advances of Diagnostic Marker for Alzheimer's Disease and Related Disorders

Wednesday, 11 February 2004 08:00 -10:00

Harbourside Auditorium 1

This symposium has been supported by an unrestricted educational grant from Eisai Co., Ltd., Pfizer Japan Inc.

Chairperson Dr Katsuya Urakami Tottori UniversityJapan

Evaluation of phosphorylated tau protein as a core biomarker of Alzheimer's disease
  • H Hampel, Ludwig-Maximilian-University, Munich, Germany
  • The use of biomarkers in the CSF for diagnosis of early alzheimer disease and mild cognitive impairment
  • Niels Andreasen, Neurotec, Karolinska Institute, Sweden
  • Clinical applications of biomarkers in Alzheimer's disease: From CSF to imaging amyloid
  • Hiroyuki Arai, Advanced Research Center for Asian Traditional Medicine, Tohoku University, Japan
  • Diagnosis of dementia and mental health strategy for the elderly
  • Masatoshi Takeda, Osaka University Graduate School of Medicine, Japan
  • How well to CSF tau and β-amyloid levels predict a patient's autopsy confirmed dementia diagnosis
  • Christopher M Clark, University of Pennsylvania, United States